[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356211-105":59,"doc-detail-356211-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","targeting-bromodomain-and-extra-terminal-proteins-reprograms-macrophages-and-inhibits-breast-cancer-progression","Targeting bromodomain and extra-terminal proteins reprograms macrophages and inhibits breast cancer progression","","Breast cancer progression is driven in part by therapy resistance and an immunosuppressive tumor microenvironment. This study investigates how BET proteins, key regulators of tumor and immune biology, shape innate anti-tumor immunity using the potent BET degrader ZBC260. In immunocompetent BALB/c D2A1 tumor-bearing mice, ZBC260 effects require macrophages and partially compromise NK cells. Single-cell RNA sequencing shows myeloid cells dominate; treatment reduces MRC1+ immunoregulatory TAMs, enriches CD74+ antigen-presenting macrophages, activates Stat1, and promotes phagosome programs, with functional in vitro tumor cell apoptosis and suppression of macrophage-driven CSC formation.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-bromodomain-and-extra-terminal-proteins-reprograms-macrophages-and-inhibits-breast-cancer-progression/356211/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-bromodomain-and-extra-terminal-proteins-reprograms-macrophages-and-inhibits-breast-cancer-progression/356211.png","ImageObject",300,407,{"name":92,"@type":93},"MrHarris58","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main therapeutic strategy evaluated in this study?","Question",{"text":113,"@type":114},"The study evaluates the potent BET degrader ZBC260 and its ability to reprogram macrophages through targeting bromodomain and extra-terminal proteins.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which innate immune cells are critical for ZBC260 efficacy?",{"text":118,"@type":114},"Macrophages are critical, as depletion partially attenuates anti-tumor and anti-CSC effects; NK cell impairment is also partially observed.",{"name":120,"@type":111,"acceptedAnswer":121},"What changes occur in tumor microenvironment populations after BETd treatment?",{"text":122,"@type":114},"Single-cell RNA sequencing identifies myeloid cells as predominant; ZBC260 reduces MRC1+ immunoregulatory TAMs while enriching CD74+ antigen-presenting macrophages, with upregulated phagosome pathways and enhanced Stat1 activation.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},356211,1790418165,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},687212988360,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","TYPE Original Research PUBLISHED 03 September 2026 DOI 10.3389/fimmu.2026.1738705  \nOPEN ACCESS  \nEDITED BY  \nPaul Takam Kamga,  \nLaboratoire d'Imagerie Biomedicale Multimodale Paris Saclay, France  \nREVIEWED BY  \nJayanta Mondal,  \nUniversity of Texas MD Anderson Cancer Center, United States  \nManjusha Biswas,  \nQMD Services GmbH, Austria  \n*CORRESPONDENCE  \nMonika L. Burness  \n [mburness@med.umich.edu](mburness@med.umich.edu)  \nRECEIVED 03 November 2025  \nREVISED 28 July 2026  \nACCEPTED 04 August 2026  \nPUBLISHED 03 September 2026  \nCITATION  \nSharma D, Hager CG, Bushnell GG, Kalman AP, Shapiro GF, Xendzova KA, Walenjus L, Hutchens CM, Wicha MS and Burness ML (2026) Targeting bromodomain and extra-terminal proteins reprograms macrophages and inhibits breast cancer progression.  \nFront. Immunol. 17:1738705 .  \ndoi: 10.3389/fimmu.2026.1738705  \nCOPYRIGHT  \n© 2026 Sharma, Hager, Bushnell, Kalman, Shapiro, Xendzova, Walenjus, Hutchens, Wicha and Burness. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nTargeting bromodomain and extra-terminal proteins reprograms macrophages and inhibits breast cancer progression  \nDeeksha Sharma 1, Cody G. Hager 1, Grace G. Bushnell 2, Alexander P. Kalman 1, Grace F. Shapiro 1, Katherine  \nA. Xendzova 1, Lynne Walenjus 1, Chloe M. Hutchens 1, Max  \nS. Wicha 1 and Monika L. Burness 1  \n1 University of Michigan Rogel Cancer Center, Internal Medicine, Ann Arbor, Michigan, IN, United States, 2 University of Minnesota, Biomedical Engineering, Minneapolis, MN, United States  \nIntroduction: Breast cancer (BC) remains a leading cause of cancer-related deaths, with resistance to therapy driving tumor progression. While immune checkpoint inhibitor (ICI) therapy is effective in some breast cancers, the heterogeneity of treatment responses is partly driven by cancer stem cells (CSCs) and an immunosuppressive tumor microenvironment (TME) . Bromodomain and extra-terminal (BET) proteins regulate tumor and immune biology, but their role in innate anti-tumor immunity remains poorly understood. We investigated the role of BET proteins in modulating innate immunity using the potent BET degrader (BETd) ZBC260 .  \nMethods: ZBC260 efﬁcacy was evaluated in immunocompetent BALB/c mice bearing D2A1 tumors. NK cells or macrophages were depleted to determine their contribution to BETd response. In vitro, primary murine NK cells, bone marrowderived macrophages, and THP-1, NK-92 MI, SUM-149, and D2A1 cells were used for co-culture, transwell migration, phagocytosis, qPCR, ELISA, and ﬂow cytometry assays. Single-cell RNA sequencing (scRNA-seq) was performed using 10x Genomics 3′ sequencing and analyzed with Seurat.  \nResults and discussion: ZBC260 inhibited tumor growth in SCID mice but not in NOD-SCID mice, with impaired macrophages and partially compromised NK cells, implicating the innate immune system. To assess the contribution of innate immune cells to BETd efﬁcacy, we depleted NK cells or macrophages in immunocompetent BALB/c mice with D2A1 tumors and treated with ZBC260 or vehicle. Immune depletion studies revealed macrophage loss partially attenuated anti-tumor and anti-CSC effects, highlighting their critical role. To understand the impact of BETd on TME populations, we performed single-cell RNA sequencing, which identiﬁed myeloid cells as the predominant population. BETd reduced MRC1⁺ immunoregulatory tumor-associated macrophages and enriched CD74+ antigen-presenting macrophages, with upregulated phagosome pathways and enhanced Stat1 activation. In vitro, BETd downregulated M2-associated markers, promoted macrophage phag","cbCainU84O0DJSfD","https://ap.wps.com/l/cbCainU84O0DJSfD","pdf",6066276,18,"English","# Introduction\n# Methods\n# Results and discussion\n# Conclusion\n# Keywords","[{\"question\":\"What is the main therapeutic strategy evaluated in this study?\",\"answer\":\"The study evaluates the potent BET degrader ZBC260 and its ability to reprogram macrophages through targeting bromodomain and extra-terminal proteins.\"},{\"question\":\"Which innate immune cells are critical for ZBC260 efficacy?\",\"answer\":\"Macrophages are critical, as depletion partially attenuates anti-tumor and anti-CSC effects; NK cell impairment is also partially observed.\"},{\"question\":\"What changes occur in tumor microenvironment populations after BETd treatment?\",\"answer\":\"Single-cell RNA sequencing identifies myeloid cells as predominant; ZBC260 reduces MRC1+ immunoregulatory TAMs while enriching CD74+ antigen-presenting macrophages, with upregulated phagosome pathways and enhanced Stat1 activation.\"}]","Targeting bromodomain and extra-terminal proteins reprograms macrophages and inhibits breast cancer progression | PDF",1790124087,45,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4b3b39d3a4dc0a9dd34ef188aaa7611b.webp",983,1389,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8da45b3273db84d8c198d6dddcaa2c1c.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f873d8243c8acec0f850cae90c9fc61b.webp",981,1386,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fd6d4f56b6fea36e682e85606125dea7.webp",980,1385]